MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION: Form 990, tax year 2021

View the entire original 990 at ProPublica ↗

Organization
MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION (EIN 31-1611837)
Tax period
2021-07-01 to 2022-06-30
Filed
2023-02-14
IRS object ID
202310459349301411
Schema version
2021v4.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2023-02-14T12:26:33-06:00ReturnTs
Tax Period End2022-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP101540102ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2021-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN311611837EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1MARC LUSTGARTEN PANCREATIC CANCERBusinessNameLine1Txt
Business Name Line2FOUNDATIONBusinessNameLine2Txt
FieldValueIRS element (for citing)
Business Name ControlMARCBusinessNameControlTxt
Phone5167371550PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DRIVE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonLINDA TANTAWIPersonNm
Person TitleCEOPersonTitleTxt
Phone5167371550PhoneNum
Signature2023-02-13SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

FieldValueIRS element (for citing)
Person FirstLINDAPersonFirstNm
Person LastTANTAWIPersonLastNm
FieldValueIRS element (for citing)
SSN999009999SSN

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonDEVIN L DUNCANPreparerPersonNm
PTINP01249521PTIN
Phone2127589700PhoneNum
Preparation2023-02-13PreparationDt

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

FieldValueIRS element (for citing)
Trusted Customer3TrustedCustomerCd
Authentication Assurance LevelAAL1AuthenticationAssuranceLevelCd
Identity Assurance LevelIAL1IdentityAssuranceLevelCd
FieldValueIRS element (for citing)
Tax2021TaxYr
Build TS2023-03-07 01:45:13ZBuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

FieldValueIRS element (for citing)
Business Name Line1LUSTGARTEN FOUNDATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Principal OfficerLINDA TANTAWIPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DRIVE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$176,264,716GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LUSTGARTEN.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1998FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SINCE ITS INCEPTION, THE LUSTGARTEN FOUNDATION HAS DIRECTED MORE THAN $250 MILLION TO RESEARCH AND HAS ASSEMBLED THE BEST SCIENTIFIC MINDS WITH THE HOPE THAT ONE DAY, A CURE CAN BE FOUND.ActivityOrMissionDesc
Voting Members Governing Body17VotingMembersGoverningBodyCnt
Voting Members Independent17VotingMembersIndependentCnt
Total Employee25TotalEmployeeCnt
Total Volunteers300TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$15,661,608PYContributionsGrantsAmt
CY Contributions Grants$20,139,699CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$7,644,241PYInvestmentIncomeAmt
CY Investment Income$10,583,001CYInvestmentIncomeAmt
PY Other Revenue$1,161,984PYOtherRevenueAmt
CY Other Revenue-$276,195CYOtherRevenueAmt
PY Total Revenue$24,467,833PYTotalRevenueAmt
CY Total Revenue$30,446,505CYTotalRevenueAmt
PY Grants And Similar Paid$15,742,900PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$25,469,007CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$3,030,185PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$4,076,717CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$697,612PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$521,137CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$3,350,144CYTotalFundraisingExpenseAmt
PY Other Expenses$2,255,332PYOtherExpensesAmt
CY Other Expenses$3,767,796CYOtherExpensesAmt
PY Total Expenses$21,726,029PYTotalExpensesAmt
CY Total Expenses$33,834,657CYTotalExpensesAmt
PY Revenues Less Expenses$2,741,804PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$3,388,152CYRevenuesLessExpensesAmt
Total Assets BOY$96,561,632TotalAssetsBOYAmt
Total Assets EOY$78,505,397TotalAssetsEOYAmt
Total Liabilities BOY$3,614,475TotalLiabilitiesBOYAmt
Total Liabilities EOY$8,473,764TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$92,947,157NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$70,031,633NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$26,550,891ExpenseAmt
Grant$25,469,007GrantAmt
DescRESEARCH PROGRAM: THE FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. TO MAKE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $25 MILLION TO RESEARCH DURING FY2022, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2022 TO $250 MILLION. SEE SCHEDULE O.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$677,642ExpenseAmt
DescPUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. SEE SCHEDULE O.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$817,430ExpenseAmt
DescPROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE LABS PROGRAM SITES, AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFICMEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. SEE SCHEDULE O.Desc
FieldValueIRS element (for citing)
Total Program Service Expenses$28,045,963TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (1)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (1)IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional FundraisingYes (1)ProfessionalFundraisingInd
Fundraising ActivitiesYes (1)FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent0BusinessRlnWith35CtrlEntInd
Deductible Non Cash ContriYes (1)DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document19IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (1)BackupWthldComplianceInd
Employee25EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo ContributionsYes (1)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (1)QuidProQuoContriDisclInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members17GoverningBodyVotingMembersCnt
Independent Voting Member17IndependentVotingMemberCnt
Family Or Business RlnYes (1)FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention PolicyYes (1)DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNVStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1FAISAL JAWAIDBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone5167371555PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DRIVE SUITE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (25 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
ANDREW LUSTGARTEN
CHAIRMAN2.000.00Yes (X)Yes (X)$0$0$0
CHARLES F DOLAN
CHAIRMAN EMERITUS2.000.00Yes (X)Yes (X)$0$0$0
ROBERT F VIZZA
CHAIRMAN EMERITUS2.000.00Yes (X)Yes (X)$0$0$0
JENNIE FORTUNOFF
SECRETARY2.000.00Yes (X)Yes (X)$0$0$0
PHILIP D'AMBROSIO
TREASURER (AS OF 5/13/22)2.000.00Yes (X)Yes (X)$0$0$0
WILLIAM BELL
TREASURER/DIRECTOR2.000.00Yes (X)Yes (X)$0$0$0
JAMES L DOLAN
VICE CHAIRMAN2.000.00Yes (X)Yes (X)$0$0$0
ADAM SILVER
VICE CHAIRMAN2.000.00Yes (X)Yes (X)$0$0$0
SOMMER BAZURO PHD
DIRECTOR (AS OF 2/9/22)2.000.00Yes (X)$0$0$0
JOHN H COBB
DIRECTOR2.000.00Yes (X)$0$0$0
JESSICA LUSTGARTEN COURTEMANCHE
DIRECTOR2.000.00Yes (X)$0$0$0
QUENTIN F DOLAN
TRUSTEE2.000.00Yes (X)$0$0$0
KENNETH GOODMAN MD FACR
DIRECTOR2.000.00Yes (X)$0$0$0
MARCIA LUSTGARTEN
DIRECTOR2.000.00Yes (X)$0$0$0
SHEILA MAHONY
DIRECTOR2.000.00Yes (X)$0$0$0
CHARLES R SCHUELER
DIRECTOR2.000.00Yes (X)$0$0$0
WILLA SHALIT
DIRECTOR2.000.00Yes (X)$0$0$0
LINDA TANTAWI
CEO40.000.00Yes (X)$385,092$0$52,597
JOHANNA RICHMAN
CFO40.000.00Yes (X)$283,726$0$42,876
KERRI KAPLAN
PRESIDENT40.000.00Yes (X)$331,122$0$34,257
CATHERINE WEBER
VP DEVELOPMENT OPS & CONSITUENT SVCS40.000.00$235,698$0$35,708Yes (X)
STEPHANIE ELSEA
VP MARKETING & COMMUNICATIONS40.000.00$205,524$0$21,012Yes (X)
ANDREW RAKEMAN
VP RESEARCH40.000.00$249,078$0$46,395Yes (X)
JASON RICE
NAT DIR OF EVENTS (END 11/21/21)40.000.00$139,771$0$5,789Yes (X)
STEPHANIE DERGARABEDIAN
NATIONAL DIRECTOR OF DEVELOPMENT40.000.00$133,480$0$37,153Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$1,963,491TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$275,787TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K8IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (4 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmtAddress Line1ContractorAddress/ForeignAddress/AddressLine1TxtCityContractorAddress/ForeignAddress/CityNmCountryContractorAddress/ForeignAddress/CountryCdForeign PostalContractorAddress/ForeignAddress/ForeignPostalCd
FAIRCOM NEW YORK INC
240 CENTRAL PARK SOUTHNEW YORKNY10019CONSULTANT$800,764
WSI PAID SEARCH LTD
TECHNOLOGY$246,1502343 EGLINTON AVENUE WESTTORONTOCAM6E2L6
JC GEEVER INC
11 RIVERSIDE DRIVENEW YORKNY10023CONSULTANT$168,534
WALKER STEWART MCKEOUGH
240 CENTRAL PARK SOUTHNEW YORKNY10019CONSULTANT$166,650
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K4CntrctRcvdGreaterThan100KCnt
Fundraising$5,630,722FundraisingAmt
All Other Contributions$14,508,977AllOtherContributionsAmt
Noncash Contributions$94,723NoncashContributionsAmt
Total Contributions$20,139,699TotalContributionsAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,693,066TotalRevenueColumnAmt
Exclusion$1,693,066ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$11,255TotalRevenueColumnAmt
Exclusion$11,255ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$154,420,696SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$145,530,761SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$8,889,935SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$8,889,935TotalRevenueColumnAmt
Exclusion$8,889,935ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$0FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$5,630,722ContriRptFundraisingEventAmt
Fundraising Direct Expenses$287,450FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$287,450TotalRevenueColumnAmt
Exclusion-$287,450ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$30,446,505TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$10,306,806ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$25,269,054TotalAmt
Program Services$25,269,054ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$199,953TotalAmt
Program Services$199,953ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$1,221,077TotalAmt
Program Services$346,045ProgramServicesAmt
Management And General$627,562ManagementAndGeneralAmt
Fundraising$247,470FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$1,792,507TotalAmt
Program Services$824,285ProgramServicesAmt
Management And General$432,239ManagementAndGeneralAmt
Fundraising$535,983FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$115,076TotalAmt
Program Services$44,690ProgramServicesAmt
Management And General$40,469ManagementAndGeneralAmt
Fundraising$29,917FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$318,175TotalAmt
Program Services$123,564ProgramServicesAmt
Management And General$111,894ManagementAndGeneralAmt
Fundraising$82,717FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$629,882TotalAmt
Program Services$237,831ProgramServicesAmt
Management And General$234,664ManagementAndGeneralAmt
Fundraising$157,387FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$521,137TotalAmt
Fundraising$521,137FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$153,022TotalAmt
Management And General$153,022ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$654,002TotalAmt
Program Services$199,774ProgramServicesAmt
Management And General$387,796ManagementAndGeneralAmt
Fundraising$66,432FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$692,413TotalAmt
Fundraising$692,413FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$458,281TotalAmt
Program Services$201,644ProgramServicesAmt
Management And General$73,325ManagementAndGeneralAmt
Fundraising$183,312FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$255,086TotalAmt
Program Services$114,789ProgramServicesAmt
Management And General$38,263ManagementAndGeneralAmt
Fundraising$102,034FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$40,694TotalAmt
Program Services$6,104ProgramServicesAmt
Management And General$8,139ManagementAndGeneralAmt
Fundraising$26,451FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$88,196TotalAmt
Program Services$38,807ProgramServicesAmt
Management And General$14,111ManagementAndGeneralAmt
Fundraising$35,278FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$45,094TotalAmt
Program Services$20,293ProgramServicesAmt
Management And General$6,764ManagementAndGeneralAmt
Fundraising$18,037FundraisingAmt

Other Expenses OtherExpensesGrp (3 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
DIRECT MAIL DESIGN & PR$1,163,972$403,160$295,223$465,589
BANK & CREDIT CARD FEES$201,066$15,079$185,987
RESEARCH SUPPORT$15,970$15,970

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$33,834,657TotalAmt
Program Services$28,045,963ProgramServicesAmt
Management And General$2,438,550ManagementAndGeneralAmt
Fundraising$3,350,144FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$4,253,446BOYAmt
EOY$2,308,831EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$515,050BOYAmt
EOY$1,982,801EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$1,508,338BOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

FieldValueIRS element (for citing)
EOY$1,234EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$190,633BOYAmt
EOY$211,815EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$388,811LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$193,616LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$131,630BOYAmt
EOY$195,195EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$89,962,535BOYAmt
EOY$73,805,521EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$96,561,632BOYAmt
EOY$78,505,397EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$533,611BOYAmt
EOY$760,077EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$2,997,905BOYAmt
EOY$7,629,947EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$82,959BOYAmt
EOY$83,740EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$3,614,475BOYAmt
EOY$8,473,764EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$92,560,157BOYAmt
EOY$68,371,633EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$387,000BOYAmt
EOY$1,660,000EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$92,947,157BOYAmt
EOY$70,031,633EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$96,561,632BOYAmt
EOY$78,505,397EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss-$3,388,152ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst-$19,527,372NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Separate Basis Fincl StmtYes (X)SeparateBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$12,048,978CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$15,969,356CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$13,046,433CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$15,661,608CurrentTaxYearMinus1YearAmt
Current Tax Year$20,139,699CurrentTaxYearAmt
Total$76,866,074TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$12,048,978CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$15,969,356CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$13,046,433CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$15,661,608CurrentTaxYearMinus1YearAmt
Current Tax Year$20,139,699CurrentTaxYearAmt
Total$76,866,074TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$13,530,515SubstantialContributorsTotAmt
Public Support Total170$63,335,559PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$515,595CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,755,392CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,417,283CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$3,252,026CurrentTaxYearMinus1YearAmt
Current Tax Year$1,704,321CurrentTaxYearAmt
Total$9,644,617TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$99,169CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$371,093CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$219,523CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$8,150CurrentTaxYearMinus1YearAmt
Total$697,935TotalAmt
FieldValueIRS element (for citing)
Total Support$87,208,626TotalSupportAmt
Public Support CY1700.72630PublicSupportCY170Pct
Public Support PY1700.55270PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE A, PART IIFormAndLineReferenceDesc
ExplanationTHE FOUNDATION CHANGED ITS FISCAL YEAR END DATE TO JUNE 30TH IN 2018, RESULTING IN A SHORT PERIOD TAX YEAR OF SIX MONTHS FROM JANUARY 1 - JUNE 30, 2018. AS A RESULT, AMOUNTS REPORTED IN COLUMN (A) REFLECT AMOUNTS FOR THE SHORT PERIOD JANUARY 1, 2018 - JUNE 30, 2018.ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$5,865OtherCostOrOtherBasisAmt
Depreciation$5,865DepreciationAmt
Book Value$0BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$18,631OtherCostOrOtherBasisAmt
Depreciation$10,398DepreciationAmt
Book Value$8,233BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$364,315OtherCostOrOtherBasisAmt
Depreciation$177,353DepreciationAmt
Book Value$186,962BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$195,195TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescDEFERRED RENT OBLIGATIONDesc
Amt$83,740Amt
FieldValueIRS element (for citing)
Total Liability$83,740TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$10,946,804TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst-$19,527,372NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$180,693DonatedServicesAndUseFcltsAmt
Revenue Not Reported-$19,346,679RevenueNotReportedAmt
Revenue Subtotal$30,293,483RevenueSubtotalAmt
Investment Expenses Not Incld$153,022InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt$153,022RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$30,446,505TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$33,862,328TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$180,693DonatedServicesUseFcltsAmt
Expenses Not Reported$180,693ExpensesNotReportedAmt
Expenses Subtotal$33,681,635ExpensesSubtotalAmt
Investment Expenses Not Incld2$153,022InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt$153,022ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$33,834,657TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART X, LINE 2:FormAndLineReferenceDesc
ExplanationTHE FOUNDATION HAS RECEIVED A FINAL DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE STATING THAT THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). THE FOUNDATION IS TREATED AS A PUBLIC CHARITY AS DEFINED IN SECTIONS 509(A)(1) AND 170(B)(1)(A)(VI). THE FOUNDATION FOLLOWS THE PROVISIONS OF ACCOUNTING STANDARDS CODIFICATION (ASC) SUBTOPIC 740-10, INCOME TAXES - OVERALL (ASC 740-10), RELATING TO UNCERTAINTY IN INCOME TAXES. FOR THE FOUNDATION, ASC 740-10 IS PRIMARILY APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME TAX ATTRIBUTABLE TO CERTAIN OF ITS INVESTMENTS. ASC 740-10 ESTABLISHES A MINIMUM THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION OF THE BENEFITS OF POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, IN FILING TAX RETURNS. IT REQUIRES THE EVALUATION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN, IN THE COURSE OF PREPARING THE FOUNDATION'S INCOME TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS ARE "MORE LIKELY THAN NOT" OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. TAX POSITIONS NOT DEEMED TO MEET THE MORE-LIKELY THAN-NOT THRESHOLD ARE RECORDED AS TAX EXPENSE. FOR THE YEARS ENDED JUNE 30, 2022 AND 2021, THE FOUNDATION HAS NOT IDENTIFIED OR PROVIDED FOR ANY SUCH POSITIONS.ExplanationTxt

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp

FieldValueIRS element (for citing)
RegionNORTH AMERICARegionTxt
Offices0OfficesCnt
Employee0EmployeeCnt
Type Of Activities ConductedGRANTMAKINGTypeOfActivitiesConductedTxt
Specific Services ProvidedPANCREATIC CANCER RESEARCHSpecificServicesProvidedTxt
Region Total Expenditures$199,953RegionTotalExpendituresAmt
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees0SubtotalEmployeesCnt
Continuation Total Office0ContinuationTotalOfficeCnt
Continuation Total Employee0ContinuationTotalEmployeeCnt
Total Office0TotalOfficeCnt
Total Employee0TotalEmployeeCnt
Subtotal Spent$199,953SubtotalSpentAmt
Continuation Spent$0ContinuationSpentAmt
Total Spent$199,953TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp

FieldValueIRS element (for citing)
RegionNORTH AMERICARegionTxt
Purpose Of GrantPANCREATIC CANCER RESEARCHPurposeOfGrantTxt
Cash Grant$199,953CashGrantAmt
Manner Of Cash DisbursementWIRE/EFTMannerOfCashDisbursementTxt
Non Cash Assistance$0NonCashAssistanceAmt
FieldValueIRS element (for citing)
Total501c3 Org1Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt
Transfer To Foreign Corp0TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp Ownership0ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 2:GRANT MONITORING PROCESS THE ORGANIZATION REQUIRES ALL GRANTEES TO PROVIDE DETAILED REPORTING ON THEIR RESEARCH. THAT REPORTING INCLUDES ACCOUNTING FOR ALL FUNDS AND SHALL BE ACCOMPANIED BY ELECTRONIC COPIES OF ALL ARTICLES, IRRESPECTIVE OF WHETHER THEY WERE PUBLISHED, PRESENTED OR OTHERWISE DISCLOSED, CONCERNING GRANT RESEARCH WRITTEN BY THE PRINCIPAL INVESTIGATOR. FINAL GRANT ACCOUNTING IS DUE FROM THE SPONSORING INSTITUTION AND THE INSTITUTIONS AGREE TO REFUND ANY PORTION OF THE GRANT FUNDS TO THE FOUNDATION THAT WAS NOT USED FOR THE SPECIFIED PURPOSES DESCRIBED HEREIN AND RETURN TO THE FOUNDATION ANY UNEXPENDED FUNDS WITHIN THIRTY (30) DAYS AFTER THE EXPIRATION OR TERMINATION OF THE GRANT TERM, OR AT THE FOUNDATION'S OPTION, THE FOUNDATION MAY, BY WRITTEN NOTICE, ALLOW THE SPONSORING INSTITUTION TO USE ANY REMAINING GRANT FUNDS IN FURTHERANCE OF GRANT RESEARCH IN PROGRESS AT THE TIME OF SUCH EXPIRATION. THE FOUNDATION SHALL HAVE THE RIGHT TO AUDIT THE USE OF GRANT FUNDS.
PART III ACCOUNTING METHOD:

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (1)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndGross ReceiptsGrossReceiptsAmtRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
BUCKLEY EVENTS
17 MARBLE AVE 19PLEASANTVILLENY10570EVENT CONSULTING0$1,123,066$40,000$1,083,066
FAIRCOM NEW YORK
12 WEST 27TH STNEW YORKNY10001DIRECT MAIL & MARKETING0$1,105,639$381,915$723,724
JC GREEVER INC
11 RIVERSIDE DR 2 EWNEW YORKNY10023DONOR MANAGEMENT0$845,044$99,222$745,822
FieldValueIRS element (for citing)
Total Gross Receipts$3,073,749TotalGrossReceiptsAmt
Total Retained By Contractors$521,137TotalRetainedByContractorsAmt
Total Net To Organization$2,552,612TotalNetToOrganizationAmt
Licensed StatesALLicensedStatesCd
Licensed StatesARLicensedStatesCd
Licensed StatesCALicensedStatesCd
Licensed StatesCOLicensedStatesCd
Licensed StatesCTLicensedStatesCd
Licensed StatesFLLicensedStatesCd
Licensed StatesGALicensedStatesCd
Licensed StatesHILicensedStatesCd
Licensed StatesILLicensedStatesCd
Licensed StatesKSLicensedStatesCd
Licensed StatesKYLicensedStatesCd
Licensed StatesMELicensedStatesCd
Licensed StatesMDLicensedStatesCd
Licensed StatesMALicensedStatesCd
Licensed StatesMILicensedStatesCd
Licensed StatesMNLicensedStatesCd
Licensed StatesMOLicensedStatesCd
Licensed StatesNVLicensedStatesCd
Licensed StatesNHLicensedStatesCd
Licensed StatesNJLicensedStatesCd
Licensed StatesNMLicensedStatesCd
Licensed StatesNYLicensedStatesCd
Licensed StatesNCLicensedStatesCd
Licensed StatesOHLicensedStatesCd
Licensed StatesOKLicensedStatesCd
Licensed StatesORLicensedStatesCd
Licensed StatesPALicensedStatesCd
Licensed StatesSCLicensedStatesCd
Licensed StatesTNLicensedStatesCd
Licensed StatesUTLicensedStatesCd
Licensed StatesVALicensedStatesCd
Licensed StatesWALicensedStatesCd
Licensed StatesWVLicensedStatesCd
Licensed StatesWILicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1BASHEvent1Nm
Gross Receipts Event1$1,123,066GrossReceiptsEvent1Amt
Charitable Contri Event1$1,123,066CharitableContriEvent1Amt
Food And Beverage Event1$140,425FoodAndBeverageEvent1Amt
Entertainment Event1$5,740EntertainmentEvent1Amt
Event2LI WALKEvent2Nm
Gross Receipts Event2$791,486GrossReceiptsEvent2Amt
Charitable Contri Event2$791,486CharitableContriEvent2Amt
Food And Beverage Event2$1,119FoodAndBeverageEvent2Amt
Other Events Total274OtherEventsTotalCnt
Gross Receipts Other Events$3,716,170GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$3,716,170CharitableContriOtherEventsAmt
Oth Direct Expnss Other Events$140,166OthDirectExpnssOtherEventsAmt
Gross Receipts Total$5,630,722GrossReceiptsTotalAmt
Charitable Contributions Tot$5,630,722CharitableContributionsTotAmt
Food And Beverage Total Events$141,544FoodAndBeverageTotalEventsAmt
Entertainment Total Events$5,740EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$140,166OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$287,450DirectExpenseSummaryEventsAmt
Net Income Summary-$287,450NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (17 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtNon Cash AssistanceNonCashAssistanceAmtPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
STAND UP TP CANCER - ENTERTAINMENT INDUSTRY FOUNDATION
10880 WILSHIRE BOULDVARD SUITE 1400LOS ANGELESCA90024951644609501(C)(3)$6,472,317$0PANCREATIC CANCER RESEARCH
JOHNS HOPKINS UNIVERSITY
1650 ORLEANS STREETBALTIMOREMD21287520595110501(C)(3)$5,174,114$0PANCREATIC CANCER RESEARCH
BREAK THROUGH CANCER
PO BOX 390450 770 MASSACHUSETTS AVECAMBRIDGEMA02139851681659501(C)(3)$5,000,000$0PANCREATIC CANCER RESEARCH
COLD SPRING HARBOR LABORATORY
ONE BUNGTOWN ROAD COLD SPRINGNEW YORKNY11724112013303501(C)(3)$1,658,716$0PANCREATIC CANCER RESEARCHHARBOR
AMERICAN ASSOCIATION FOR CANCER RESEARCH
615 CHESTNUT STREET- 17TH FLOORPHILADELPHIAPA191064404236251648501(C)(3)$1,390,839$0PANCREATIC CANCER RESEARCH
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
77 MASSACHUSETTS AVENUECAMBRIDGEMA02139042103594501(C)(3)$1,317,682$0PANCREATIC CANCER RESEARCH
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02215042263040501(C)(3)$1,200,000$0PANCREATIC CANCER RESEARCH
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 W 131ST STREET 4TH FLOORNEW YORKNY10027135598093501(C)(3)$787,439$0PANCREATIC CANCER RESEARCH
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
10010 NORTH TORREY PINES ROADLA JOLLACA92037952160097501(C)(3)$530,000$0PANCREATIC CANCER RESEARCH
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
PO BOX 741539LOS ANGELESCA90074956006144501(C)(3)$455,000$0PANCREATIC CANCER RESEARCH
YALE UNIVERSITY
PO BOX 1873NEW HAVENCT06508060646973501(C)(3)$299,640$0PANCREATIC CANCER RESEARCH
MASSACHUSETTES GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA02114042697983501(C)(3)$250,000$0PANCREATIC CANCER RESEARCH
NYU GROSSMAN SCHOOL OF MEDICINE
PO BOX 415026BOSTONMA02241135562308501(C)(3)$200,000$0PANCREATIC CANCER RESEARCH
THE TRUSTEE OF THE UNIVERSITY OF PENNSYLVANIA
3400 CIVIC CENTER BLVDPHILADELPHIAPA19104231352685501(C)(3)$200,000$0PANCREATIC CANCER RESEARCH
OREGON HEALTH AND SCIENCE
2730 SW MOODY AVENUEPORTLANDOR97201931176109GOVT$198,307$0PANCREATIC CANCER RESEARCH
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
104 AIRPORT DRIVE SUITE 2200 CAMPUSCHAPEL HILLNC27599566001393501(C)(3)$75,000$0PANCREATIC CANCER RESEARCHBOX 1350
HENRY FORD HEALTH SYSTEM
2799 W GRAND BLVDDETROITMI48202381357020501(C)(3)$60,000$0PANCREATIC CANCER RESEARCH
FieldValueIRS element (for citing)
Total501c3 Org17Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 2:FormAndLineReferenceDesc
ExplanationTHE FOUNDATION MAKES GRANTS TO 501(C)(3) PUBLIC CHARITIES CONDUCTING PANCREATIC CANCER RESEARCH. AS PART OF THE REQUIREMENT FOR RECEIVING SUCH GRANTS, THE FOUNDATION REQUIRES PERIODIC UPDATES AND REPORTING ON SCIENTIFIC PROGRESS AND FINANCIAL EXPENDITURES.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (1)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (1)SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (1)AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
LINDA TANTAWI
CEO$318,738$0$66,354$0$0$0$10,900$0$41,697$0$437,689$0$0$0
KERRI KAPLAN
PRESIDENT$263,267$0$67,855$0$0$0$0$0$34,257$0$365,379$0$0$0
JOHANNA RICHMAN
CFO$219,303$0$37,500$0$26,923$0$9,923$0$32,953$0$326,602$0$0$0
ANDREW RAKEMAN
VP RESEARCH$206,078$0$43,000$0$0$0$7,344$0$39,051$0$295,473$0$0$0
CATHERINE WEBER
VP DEVELOPMENT OPS & CONSITUENT SVCS$195,698$0$40,000$0$0$0$8,000$0$27,708$0$271,406$0$0$0
STEPHANIE ELSEA
VP MARKETING & COMMUNICATIONS$170,524$0$35,000$0$0$0$7,000$0$14,012$0$226,536$0$0$0
STEPHANIE DERGARABEDIAN
NATIONAL DIRECTOR OF DEVELOPMENT$118,972$0$14,508$0$0$0$5,031$0$32,122$0$170,633$0$0$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINES 4A-BPART I, LINE 4A: SEVERANCE COMPENSATION JASON RICE, NATIONAL DIRECTOR OF EVENTS, RECEIVED A SEVERANCE PAYMENT OF $15,000 IN CALENDAR YEAR 2021. PART I, LINE 4: SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN LINDA TANTAWI, CEO, PARTICIPATES IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN, AND $3,900 OF DEFERRED COMPENSATION RELATED TO THE PLAN IS REPORTED ON SCHEDULE J, PART II, COLUMN (C).
PART I, LINE 7NONFIXED PAYMENTS IN 2021, OFFICERS AND EMPLOYEES RECEIVED NONFIXED DISCRETIONARY BONUSES AS REPORTED ON SCHEDULE J, PART II, COLUMN (B)(II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution25ContributionCnt
Noncash Contributions Rpt F990$94,723NoncashContributionsRptF990Amt
Method Of Determining RevenuesAVG MKT VALUEMethodOfDeterminingRevenuesTxt
FieldValueIRS element (for citing)
Any Property That Must Be Held0AnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (1)ReviewProcessUnusualNCGiftsInd
Third Parties Used0ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PART I, COLUMN (B)FormAndLineReferenceDesc
ExplanationTHE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4ARESEARCH PROGRAM $26,550,891 GRANTS $25,469,007 THE FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. TO MOVE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $25 MILLION TO RESEARCH DURING FY2022, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2022 TO $250 MILLION. BECAUSE RESEARCH IS FUNDAMENTAL AND PROGRESS IS PARAMOUNT, THE FOUNDATION HAS SUPPORTED NEARLY 320 PROJECTS WORLDWIDE, WITH PARTNERSHIPS AT MORE THAN 80 ACADEMIC INSTITUTIONS. DURING FY2022, MAJOR LUSTGARTEN-FUNDED RESEARCH MILESTONES AND ACHIEVEMENTS HAVE FOCUSED ON: STRETCHING THE BOUNDARIES OF SCIENCE THROUGH CLINICAL TRIALS: THE FOUNDATION ESTABLISHED THE CLINICAL ACCELERATOR INITIATIVE (CAI) TO SHORTEN THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING CUTTING-EDGE BIOMARKERS. THESE "SMARTER" CLINICAL TRIALS WILL GENERATE LARGE VOLUMES OF DATA THAT SCIENTISTS CAN USE NOW AND, IN THE FUTURE, TO INFORM AND IMPROVE CLINICAL TRIALS AND EXPEDITE NEW TREATMENTS. IN 2022, THE FOUNDATION APPROVED $1.5 MILLION TO FUND ONE CAI CLINICAL TRIAL BASED AT MASSACHUSETTES GENERAL HOSPITAL AND $3.3 MILLION TO SUPPORT THE DEVELOPMENT OF A DEDICATED CLINICAL SCIENCE DATABASE WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. THE TRANSLATIONAL ADVISORY GROUP, LED BY CHIEF MEDICAL ADVISOR DR. ELIZABETH JAFFEE AND COMPRISED OF RENOWNED PANCREATIC CANCER EXPERTS, GUIDES THE CAI BY IDENTIFYING, REVIEWING AND DEVELOPING THE BEST TRANSLATIONAL PROJECTS TO IMPACT PATIENT CARE IN THE CLINIC. THE TRANSLATIONAL ADVISORY GROUP IS BUILDING A NETWORK OF SITES TO EXECUTE THE PROPOSED RESEARCH IN SMALL CLINICAL TRIALS OF 10-20 PATIENTS EACH. THESE SCIENCE-DRIVEN STUDIES COULD DRAMATICALLY INFORM RESEARCH, ENABLING INVESTIGATORS TO QUICKLY DETERMINE IF PATIENTS ARE RESPONDING TO SPECIFIC TREATMENT APPROACHES AND WHY - INFORMATION THAT WILL HELP ENHANCE CLINICAL TRIALS AND ULTIMATELY, CLINICAL CARE. LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM: A HALLMARK OF THE LUSTGARTEN FOUNDATION'S UNIQUE RESEARCH STRATEGY, THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE. THE LABS PROGRAM IS COMMITTED TO SHARING EXPERTISE ACROSS DIVERSE FIELDS, WITH THE GOAL OF ADVANCING KNOWLEDGE AND REFINING OUR COLLECTIVE UNDERSTANDING OF COMPLEX SYSTEMS AND PATHWAYS. THE SIX LABS PROGRAM SITES ARE: - COLD SPRING HARBOR LABORATORY (LONG ISLAND, NEW YORK) FOCUSING ON PERSONALIZED MEDICINE, DR. DAVID TUVESON LEADS THE LABS SITE AT COLD SPRING HARBOR LABORATORY, DESIGNING NEW MODELS OF THE DISEASE AND DISCOVERING NOVEL THERAPEUTIC AND DIAGNOSTIC PLATFORMS TO BRING NEW OPTIONS TO PATIENTS MORE RAPIDLY. DR. TUVESON WAS THE FIRST SCIENTIST TO DEVELOP A PANCREATIC CANCER ORGANOID - A THREE-DIMENSIONAL CELL CULTURE SYSTEM WHICH REPRODUCES A PATIENT'S TUMOR. THIS ENABLES RESEARCHERS TO REPEATEDLY TEST THE EFFECTIVENESS OF DIFFERENT DRUGS TO ACCURATELY PREDICT HOW A PATIENT WILL RESPOND TO VARIOUS THERAPIES, OFFERING THE HOPE OF PERSONALIZED CANCER TREATMENTS. IN ADDITION TO OTHER PROJECTS, THE LAB'S ORGANOID FACILITY IS GROWING AND TESTING ORGANOIDS FOR THE ONGOING PASS-01 CLINICAL TRIAL. - DANA-FARBER CANCER INSTITUTE (BOSTON, MASSACHUSETTS) LEARNING FROM PATIENTS TO ADVANCE RESEARCH UNDER THE LEADERSHIP OF DR. BRIAN WOLPIN, THE LABS SITE AT DANA-FARBER IS A CRITICAL HUB FOR ADVANCING RESEARCH FROM THE LABORATORY TO THE CLINIC, INITIATING SCIENTIFICALLY-DRIVEN CLINICAL TRIALS AND IDENTIFYING NEW APPROACHES TO EARLY INTERCEPTION/DETECTION. DR. WOLPIN AND HIS TEAM ARE ALSO ANALYZING PANCREATIC CANCER SUBTYPES TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE AND THE GENETIC DRIVERS THAT DETERMINE EACH SUBTYPE. HE IS EVALUATING NEW, PERSONALIZED TREATMENT APPROACHES BASED ON MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF THE PATIENT'S TUMOR. - JOHNS HOPKINS (BALTIMORE, MARYLAND) GUIDED BY GENETICS, FOCUSED ON PANCREATIC CANCER DIRECTED BY DR. BERT VOGELSTEIN, THE LABS SITE AT JOHNS HOPKINS IS USING ITS EXPERTISE IN EARLY DETECTION AND INTERCEPTION OF PANCREATIC CANCER TO DISCOVER PANCREATIC CANCER AT AN EARLIER STAGE, WHEN PATIENTS MAY BE SURGICAL CANDIDATES, AND IS DEVELOPING NEW THERAPEUTIC APPROACHES BASED ON GENETIC ALTERATIONS. IN 2021, EXACT SCIENCES ACQUIRED THE RIGHTS TO CANCERSEEK, A POWERFUL BLOOD TEST CAPABLE OF DETECTING THE EARLY PRESENCE OF MULTIPLE CANCERS AND DEVELOPED THROUGH LUSTGARTEN FUNDING AT THE JOHNS HOPKINS LABS SITE. EXACT SCIENCES IS PREPARING TO INITIATE A 100,000-PERSON REGISTRATION TRIAL AS A STEP TOWARD FDA APPROVAL. (PLEASE SEE EARLY EVENTS OF PANCREATIC CANCER WITHIN THIS DOCUMENT FOR MORE INFORMATION ON EARLY DETECTION ADVANCEMENTS.) - JOHNS HOPKINS (BALTIMORE, MARYLAND) ADVANCING IMMUNOLOGY LED BY DR. ELIZABETH JAFFEE, THE SECOND LABS SITE AT JOHNS HOPKINS IS WORKING TO BRING NOVEL THERAPIES FOR PANCREATIC CANCER TO THE CLINIC AS QUICKLY AS POSSIBLE. BUILDING ON DECADES OF EXPERIENCE AND EXPERTISE IN THE IMMUNOLOGY OF PANCREATIC CANCER, DR. JAFFEE AND HER TEAM ARE FOCUSING ON IMMUNE THERAPIES AND DEVELOPING APPROACHES TO BRING THE BENEFITS OF THIS REVOLUTIONARY APPROACH TO TREATING TUMORS TO PANCREATIC CANCER. - MASSACHUSETTS INSTITUTE OF TECHNOLOGY (CAMBRIDGE, MASSACHUSETTS) USING TECHNOLOGY TO INCREASE PRECISION IN PANCREATIC CANCER RESEARCH THE LABS SITE AT MIT IS LEVERAGING ITS UNPARALLELED EXPERTISE IN CANCER BIOLOGY AND ENGINEERING TO ADVANCE PANCREATIC CANCER RESEARCH. LED BY DR. TYLER JACKS, THE LABORATORY IS STUDYING GENETIC EVENTS CONTRIBUTING TO CANCER DEVELOPMENT AND EXAMINING THE IMMUNE RESPONSES TO THE DISEASE USING MOLECULAR PROFILING TO IDENTIFY TUMOR MUTATIONS. DR. JACKS AND HIS TEAM ALSO ARE RUNNING PRECLINICAL TRIALS IN MOUSE MODEL SYSTEMS TO SEE WHICH DRUGS AND DRUG COMBINATIONS WORK BEST TO BRING ABOUT A PROPER IMMUNE RESPONSE AGAINST PANCREATIC CANCER. - SALK INSTITUTE FOR BIOLOGICAL STUDIES (LA JOLLA, CALIFORNIA) NEW APPROACHES, NEW TARGETS THE LABS (LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE) SITE AT THE SALK INSTITUTE IS LED BY FOUR CO-PRINCIPAL INVESTIGATORS: PROFESSORS REUBEN SHAW, RONALD EVANS, TONY HUNTER, AND DANNIELLE ENGLE. THESE RESEARCHERS AND THEIR TEAMS ARE EXPLORING UNIQUE AND UNDERSTUDIED AREAS RELATED TO DIAGNOSING AND TREATING PANCREATIC CANCER AND ARE FOCUSED ON IDENTIFYING AND VALIDATING NEW TARGETS FOR PANCREATIC CANCER DRUGS AND BIOMARKERS. REUBEN SHAW, PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND WILLIAM R. BRODY CHAIR, EXPLORES THE ROLE OF LIPID METABOLISM. RONALD EVANS, PROFESSOR IN THE GENE EXPRESSION LABORATORY AND MARCH OF DIMES CHAIR IN MOLECULAR AND DEVELOPMENT BIOLOGY, INVESTIGATES TRANSCRIPTIONAL AND EPIGENETIC TARGETS. TONY HUNTER, AMERICAN CANCER SOCIETY PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND RENATO DULBECCO CHAIR, WILL CONTINUE HIS RENOWNED EXPLORATION OF KINASE DRUG TARGETS. DANNIELLE ENGLE, ASSISTANT PROFESSOR IN THE REGULATORY BIOLOGY LABORATORY, ADDRESSES VULNERABILITIES IN GLYCANS, CARBOHYDRATES THAT COAT PROTEINS AND CELLS. MICHAEL DOWNES, SENIOR STAFF SCIENTIST IN THE GENE EXPRESSION LABORATORY, WILL OVERSEE THE CENTRAL CORE FACILITY STUDYING CHANGES IN PANCREATIC CANCER, AND DEVELOPING NEW MODELS AND THERAPEUTIC APPROACHES.
FORM 990, PART III, LINE 4AUNDERSTANDING THE EARLY EVENTS OF PANCREATIC CANCER: ALISON KLEIN, PHD, JOHNS HOPKINS SCHOOL OF MEDICINE, IS USING UPDATED WAYS OF SEQUENCING GENES TO DETERMINE IF THERE ARE OTHER GENES BESIDES THE ONES ALREADY KNOWN TO INCREASE THE RISK FOR PANCREATIC CANCER IN FAMILIES. THIS IS CRITICAL BECAUSE IN APPROXIMATELY 80% OF FAMILIES WITH INHERITED PANCREATIC CANCER, THE GENE CAUSING THE RISK IS UNKNOWN. DR. KLEIN AIMS TO IDENTIFY GENETIC CAUSES OF FAMILIAL PANCREATIC CANCER; DISCOVER NEW CANDIDATE PANCREATIC CANCER GENES THAT WERE NOT FOUND USING SHORT-READ SEQUENCING; IDENTIFY FAMILIES WITH GENETIC VARIANTS IN KNOWN PANCREATIC CANCER GENES THAT WERE MISSED USING CONVENTIONAL SEQUENCING APPROACHES; CREATE NEW ALGORITHMS TO IDENTIFY THE CAUSE OF INHERITED DISEASE INCLUDING CANCERS; AND DEVELOP EFFECTIVE METHODS FOR LARGE-SCALE, LONG-RANGE GENOMIC SEQUENCING SO DOCTORS CAN MONITOR FOR RISK IN THEIR PATIENTS. LAURA WOOD, MD, PHD, JOHNS HOPKINS UNIVERSITY, DEVELOPED CODA, A THREE-DIMENSIONAL MODELING TECHNIQUE USING SLICES OF TISSUES TO BUILD A MODEL SHOWING WHAT HAPPENS WHEN CELLS TOUCH OTHER CELLS TO DETERMINE IF THAT INTERACTION HAS AN IMPACT ON PANCREATIC CANCER DEVELOPMENT. USING CODA, SHE WILL ANALYZE NORMAL PANCREATIC TISSUE AND EXAMINE THE SPECIFIC CELLULAR AND MOLECULAR CHANGES THAT OCCUR IN OLDER PATIENTS WHO ARE AT AN INCREASED FAMILIAL RISK. DR. WOOD IS ALSO EXAMINING PEOPLE WITH PRECANCEROUS LESIONS CALLED PANINS TO UNDERSTAND WHAT CAUSES A LESION TO CHANGE FROM BENIGN, WHICH REQUIRES MONITORING, TO MALIGNANT, WHICH REQUIRES SURGICAL INTERVENTION. IDENTIFYING NOVEL THERAPEUTIC APPROACHES: THE FOUNDATION'S THERAPEUTICS-FOCUSED RESEARCH PROGRAM WAS CREATED TO ENSURE A ROBUST AND FLOURISHING PIPELINE OF POTENTIAL TREATMENTS AND TO ENABLE COLLABORATION. TO DATE, THE THERAPEUTICS-FOCUSED RESEARCH PROGRAM HAS AWARDED 10 GRANTS TOTALING $11.2 MILLION. FUNDED PROJECTS ADDRESS FOUR KEY AREAS OF PANCREATIC CANCER BIOLOGY: - LEARNING HOW THE STROMA - THE SUPPORTIVE TISSUE SURROUNDING THE PANCREATIC TUMOR - MAY HELP PROTECT TUMORS FROM THE IMMUNE SYSTEM AND RESIST THERAPIES. - UNDERSTANDING AND DISCOVERING HOW TO BLOCK THE INFLAMMATORY SIGNALS THAT CAN LEAD TO PANCREATIC CANCER AND OTHER PANCREATIC DISEASES IN RESPONSE TO ENVIRONMENTAL CAUSES. - DETERMINING WAYS TO STOP TUMOR CELL GROWTH BY BLOCKING THE ABNORMAL METABOLIC PATHWAYS USED BY PANCREATIC CANCER CELLS. - PREVENTING THE SPREAD - OR METASTASIS - OF CANCER BY ISOLATING METASTATIC TRIGGERS IN CANCER CELLS AND THE STROMA. EXPANDING COLLABORATION WITH STAND UP TO CANCER: THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE HAS SUPPORTED RESEARCH LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS INCLUDING NEARLY 30 CLINICAL TRIALS. IN FY22, THE COLLECTIVE FUNDED THE FOLLOWING NEW RESEARCH: AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2022 ANNUAL MEETING, VINOD BALACHANDRAN, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, PRESENTED HIS RESULTS OF THE FIRST TRIAL TESTING A PERSONALIZED MESSENGER RNA (MRNA) VACCINE. THE PHASE 1 TRIAL WAS THE CULMINATION OF YEARS OF RESEARCH LEADING TO THE CRITICAL DISCOVERY THAT LONG-TERM PANCREATIC CANCER SURVIVORS HAVE SPECIFIC IMMUNE RESPONSES THE TEAM HOPED TO MIMIC WITH THE VACCINES. THE ASCO PRESENTATION FOLLOWED THE TEAM'S SECOND PAPER PUBLISHED IN THE SCIENTIFIC JOURNAL NATURE (6/9/22). THE RESULTS SUGGEST THE POSSIBILITY OF DURABLE PROTECTION AGAINST PANCREATIC CANCER IF AN IMMUNE RESPONSE CAN BE DRIVEN AGAINST TUMOR-SPECIFIC TARGETS. THE STUDY ALSO DEMONSTRATES THE FEASIBILITY OF DEVELOPING PATIENT-SPECIFIC, PERSONALIZED VACCINES IN A CLINICALLY RELEVANT TIMEFRAME. ELIZABETH JAFFEE, MD, JOHNS HOPKINS, THE LUSTGARTEN FOUNDATION'S CHIEF MEDICAL ADVISOR, DIRECTS THE FIRST-EVER VACCINE TRIAL AIMED AT PREVENTING PANCREATIC CANCER IN HEALTHY INDIVIDUALS WITH AN ELEVATED RISK FOR THE DISEASE BASED ON THEIR GENETICS OR FAMILY HISTORY OF PANCREATIC CANCER. DR. JAFFEE'S STUDY IS ENROLLING 25 PARTICIPANTS AND WILL MEASURE THE SAFETY AND IMMUNE RESPONSE TO A VACCINE AGAINST MUTANT KRAS PROTEINS, THE MOST COMMON DRIVER OF PANCREATIC CANCER. IF DEEMED SAFE AND EFFECTIVE, THE NEXT STEP IS TO DETERMINE IF IMMUNITY AGAINST THIS MUTATED PROTEIN IS ABLE TO DELAY OR PREVENT PANCREATIC CANCER. ADDRESSING EQUITY, DIVERSITY, AND INCLUSION IN PANCREATIC CANCER RESEARCH: SOLVING THE COMPLEX PROBLEM OF PANCREATIC CANCER REQUIRES DIVERSITY OF THOUGHT, EDUCATION, TRAINING, BACKGROUND AND EXPERIENCE TO MOVE PROGRESS FORWARD. OUR COMMITMENT TO ENSURING EQUITY, DIVERSITY AND INCLUSION - ACROSS LUSTGARTEN-FUNDED RESEARCH AND THE SCIENTISTS WE SUPPORT - IS FOUNDATIONAL TO OUR MISSION TO CURE PANCREATIC CANCER. SUPPORTING DISTINGUISHED EARLY-CAREER SCIENTISTS HELPS ENSURE THEIR CONTINUED COMMITMENT TO STUDYING PANCREATIC CANCER. THE LUSTGARTEN FOUNDATION GRANTED TWO CAREER DEVELOPMENT AWARDS TO INCREASE THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS RECEIVING FUNDING FOR PANCREATIC CANCER RESEARCH. THE AWARDS PROGRAM, IN ITS SECOND YEAR, CONTINUES TO SUPPORT INVESTIGATORS COMMITTED TO INCREASING OUR UNDERSTANDING AND TREATMENT OF THIS DISEASE. THE AWARDS HONOR THE LIVES AND LEGACIES OF TWO TRAILBLAZING AMERICANS LOST TO PANCREATIC CANCER - JUSTICE RUTH BADER GINSBURG AND CONGRESSMAN JOHN ROBERT LEWIS. EACH RECIPIENT IS AWARDED A THREE-YEAR, $300,000 GRANT FOR THEIR PANCREATIC CANCER RESEARCH. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF RUTH BADER GINSBURG WAS GRANTED TO PINGPING HOU, PHD, AN ASSISTANT PROFESSOR AT RUTGERS UNIVERSITY. DR. HOU IS INVESTIGATING AN IMMUNE CELL POPULATION CALLED TUMOR ASSOCIATED MACROPHAGES (TAMS) THAT HAVE BEEN SHOWN TO CAUSE RESISTANCE IN A THERAPY TARGETING KRAS, A KEY DRIVER OF PANCREATIC CANCER. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF JOHN ROBERT LEWIS WAS GRANTED TO EDWIN MANUEL, PHD, AN ASSISTANT PROFESSOR AT THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. DR. MANUEL IS DEVELOPING NEW METHODS TO COMBAT PANCREATIC CANCER THERAPEUTIC RESISTANCE AND ADAPTATION, KEY COMPONENTS LEADING TO DISEASE PROGRESSION. PARTNERING WITH BREAK THROUGH CANCER TO ADVANCE KRAS RESEARCH: COMMITTED TO DEVELOPING A THERAPY TARGETING KRAS, A GENE MUTATED IN 90% OF PANCREATIC CANCER CASES, THE LUSTGARTEN FOUNDATION INVESTED $5 MILLION IN SUPPORT OF A 3-YEAR, $15 MILLION PROJECT WITH BREAK THROUGH CANCER ENTITLED "CONQUERING KRAS IN PANCREATIC CANCER." RESEARCHERS WILL INVESTIGATE PROMISING KRAS-TARGETING THERAPIES TO ACCELERATE THE TRANSLATION OF NEW KRAS INHIBITORS INTO EFFECTIVE DRUGS FOR THIS DISEASE. BREAK THROUGH CANCER CREATED A "TEAM LAB" STRUCTURE TO MAXIMIZE INTERDISCIPLINARY COLLABORATION AMONG RESEARCHERS FROM THE NATION'S TOP FIVE CANCER RESEARCH CENTERS (DANA-FARBER CANCER INSTITUTE, JOHNS HOPKINS, MEMORIAL SLOAN KETTERING CANCER CENTER, KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH AT MIT, AND THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER). THEY WILL WORK TOGETHER TO BOLDLY TACKLE THE BIGGEST CHALLENGES IN CANCER, WITH A FOCUS ON PANCREATIC CANCER, OVARIAN CANCER, AND GLIOBLASTOMA, WHICH ALL FACE POOR PROGNOSES AND SLOW RESEARCH PROGRESS.
FORM 990, PART III, LINE 4BPUBLIC EDUCATION AND INFORMATION PROGRAM $677,642 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTERS - ANNUAL REPORT - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - RESEARCH MILESTONES UPDATE -TIMELINE OF PANCREATIC CANCER RESEARCH MILESTONES - INCREASED FOCUS ON VIDEO, INCLUDING A VIRTUAL TOUR OF THE LUSTGARTEN LAB AT COLD SPRING HARBOR LABORATORY - PANCREATIC CANCER COLLECTIVE RADIO AND DIGITAL PUBLIC SERVICE ANNOUNCEMENTS FOCUSED ON INCREASING DIVERSITY IN CLINICAL TRIALS. WE ALSO CONTINUE DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATMENT. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG.
FORM 990, PART III, LINE 4CPROFESSIONAL EDUCATION PROGRAM $817,430 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. THE FOUNDATION BEGAN PREPARING FOR ITS ROLE AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER THAT WAS HELD IN BOSTON, MA IN SEPTEMBER 2022. THE FOUNDATION ALSO STARTED PREPARING FOR ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS IN THE BANBURY CENTER AT COLD SPRING HARBOR LABORATORY THAT WAS HELD IN OCTOBER 2022. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS.
FORM 990, PART VI, SECTION A, LINE 2CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. ANDREW LUSTGARTEN, JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN DOLAN - BUSINESS RELATIONSHIP.
FORM 990, PART VI, SECTION B, LINE 11BFORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS.
FORM 990, PART VI, SECTION B, LINE 12CTHE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE.
FORM 990, PART VI, SECTION B, LINE 15COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED.
FORM 990, PART VI, SECTION C, LINE 19AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.